Recent performance context for TG Therapeutics stock

TG Therapeutics (TGTX) has drawn investor attention after recent trading, with the stock down 2.1% over the past day and 7.8% over the past week, while remaining higher over the past month and the past 3 months.

Looking beyond the latest pullback, TG Therapeutics shares have a 30 day share price return of 8.2% and a 90 day share price return of 25.5%, while the 3 year total shareholder return of 38.3% points to momentum that has built over a longer stretch.

If TG Therapeutics has you watching biotech closely, it can be worth scanning other healthcare stocks using emerging AI tools too, starting with 39 healthcare AI stocks

With TG Therapeutics posting revenue of $700.349 million and net income of $461.896 million, and the stock trading at $36.64 against an analyst price target of $48.00, is there still upside here, or is the market already pricing in future growth?

Most Popular Narrative: 18% Undervalued

With TG Therapeutics last closing at $36.64 against a narrative fair value of $44.43, the current gap reflects a view that the market is still skeptical about how the BRIUMVI story and broader earnings path will play out.

The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35 to 40% of the anti-CD20 MS market segment currently dominated by self-administered therapies, greatly increasing BRIUMVI's addressable market and supporting long-term revenue growth.

Curious what kind of revenue runway and profit profile are being mapped out behind that fair value, and how the assumed earnings multiple compares with typical biotech peers. The full narrative spells out the growth rates, margin reset and valuation bridge analysts are using to justify that $44.43 figure.

Result: Fair Value of $44.43 (UNDERVALUED)

However, the story can change quickly if BRIUMVI underperforms against rival MS therapies or if pricing pressure from payers compresses margins faster than expected.

Next Steps

With sentiment clearly divided between risk and reward, now is the time to look through the numbers yourself and pressure test the assumptions. To weigh both sides in one place, review the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on other opportunities that fit your style, so put a few more ideas on your radar.

• Expand your hunt for quality by scanning 47 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their strengths.
• Strengthen your income shortlist by reviewing 11 dividend fortresses that aim to pair higher yields with more resilient payout profiles.
• Stay on the front foot by tracking screener containing 22 high quality undiscovered gems before they appear on everyone else's watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.